The use of adenoviral vectors in gene therapy and vaccine approaches
Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a vers...
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Sociedade Brasileira de Genética
2022-10-01
|
| Sarja: | Genetics and Molecular Biology |
| Aiheet: | |
| Linkit: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108&tlng=en |
| _version_ | 1828343523353559040 |
|---|---|
| author | Natália Meneses Araújo Ileana Gabriela Sanchez Rubio Nicholas Pietro Agulha Toneto Mirian Galliote Morale Rodrigo Esaki Tamura |
| author_facet | Natália Meneses Araújo Ileana Gabriela Sanchez Rubio Nicholas Pietro Agulha Toneto Mirian Galliote Morale Rodrigo Esaki Tamura |
| author_sort | Natália Meneses Araújo |
| collection | DOAJ |
| description | Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field. |
| first_indexed | 2024-04-13T23:44:34Z |
| format | Article |
| id | doaj.art-7b3b67ae4f4a4e57b51cec822e8747b4 |
| institution | Directory Open Access Journal |
| issn | 1678-4685 |
| language | English |
| last_indexed | 2024-04-13T23:44:34Z |
| publishDate | 2022-10-01 |
| publisher | Sociedade Brasileira de Genética |
| record_format | Article |
| series | Genetics and Molecular Biology |
| spelling | doaj.art-7b3b67ae4f4a4e57b51cec822e8747b42022-12-22T02:24:24ZengSociedade Brasileira de GenéticaGenetics and Molecular Biology1678-46852022-10-01453 suppl 110.1590/1678-4685-gmb-2022-0079The use of adenoviral vectors in gene therapy and vaccine approachesNatália Meneses AraújoIleana Gabriela Sanchez RubioNicholas Pietro Agulha TonetoMirian Galliote MoraleRodrigo Esaki Tamurahttps://orcid.org/0000-0001-7767-0887Abstract Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108&tlng=enAdenovirusgene therapymonogenic diseasescancervaccines |
| spellingShingle | Natália Meneses Araújo Ileana Gabriela Sanchez Rubio Nicholas Pietro Agulha Toneto Mirian Galliote Morale Rodrigo Esaki Tamura The use of adenoviral vectors in gene therapy and vaccine approaches Genetics and Molecular Biology Adenovirus gene therapy monogenic diseases cancer vaccines |
| title | The use of adenoviral vectors in gene therapy and vaccine approaches |
| title_full | The use of adenoviral vectors in gene therapy and vaccine approaches |
| title_fullStr | The use of adenoviral vectors in gene therapy and vaccine approaches |
| title_full_unstemmed | The use of adenoviral vectors in gene therapy and vaccine approaches |
| title_short | The use of adenoviral vectors in gene therapy and vaccine approaches |
| title_sort | use of adenoviral vectors in gene therapy and vaccine approaches |
| topic | Adenovirus gene therapy monogenic diseases cancer vaccines |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000400108&tlng=en |
| work_keys_str_mv | AT nataliamenesesaraujo theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT ileanagabrielasanchezrubio theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT nicholaspietroagulhatoneto theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT miriangalliotemorale theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT rodrigoesakitamura theuseofadenoviralvectorsingenetherapyandvaccineapproaches AT nataliamenesesaraujo useofadenoviralvectorsingenetherapyandvaccineapproaches AT ileanagabrielasanchezrubio useofadenoviralvectorsingenetherapyandvaccineapproaches AT nicholaspietroagulhatoneto useofadenoviralvectorsingenetherapyandvaccineapproaches AT miriangalliotemorale useofadenoviralvectorsingenetherapyandvaccineapproaches AT rodrigoesakitamura useofadenoviralvectorsingenetherapyandvaccineapproaches |